THE SEARLE COMPANY LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.4 PKR | +7.49% |
|
+16.02% | +17.33% |
| 2023 | Euro zone sovereign bond yields approach 8-month low ahead of US data | RE |
| 2023 | The Searle Company Limited Announces Board Changes | CI |
| Sales 2024 * | 44.08B 159M 12.66B | Sales 2025 * | 50.94B 183M 14.63B | Capitalization | 23.56B 84.75M 6.76B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.22B 4.38M 350M | Net income 2025 * | 2.88B 10.37M 828M | EV / Sales 2024 * | 1.06 x |
| Net Debt 2024 * | 22.97B 82.64M 6.6B | Net Debt 2025 * | 22.21B 79.9M 6.38B | EV / Sales 2025 * | 0.9 x |
| P/E ratio 2024 * |
23.3
x | P/E ratio 2025 * |
10.7
x | Employees | 2,716 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.07% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +7.49% | ||
| 1 week | +16.02% | ||
| Current month | +12.50% | ||
| 1 month | -0.56% | ||
| 3 months | +20.87% | ||
| 6 months | +29.17% | ||
| Current year | +17.33% |
1 week
52.85
60.40
1 month
51.5062.25
Current year
43.0363.05
1 year
34.2264.09
3 years
34.22163.78
5 years
34.22178.46
10 years
29.70315.61
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 31/12/07 | |
Mobeen Alam
DFI | Director of Finance/CFO | - | 22/10/14 |
Imtiaz Haider
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 31/12/07 | |
| Director/Board Member | 60 | - | |
Munis Abdullah
BRD | Director/Board Member | - | 25/02/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/05/24 | 60.4 | +7.49% | 27,648,760 |
| 08/05/24 | 56.19 | +2.57% | 7,108,450 |
| 07/05/24 | 54.78 | +0.87% | 6,928,711 |
| 06/05/24 | 54.31 | +3.53% | 6,982,454 |
| 03/05/24 | 52.46 | +0.77% | 2,990,751 |
End-of-day quote Pakistan S.E., May 08, 2024
More quotes
The Searle Company Limited is a Pakistan-based company, which is engaged in the manufacture of pharmaceuticals and other consumer products. The Companyâs product categories include pharmaceutical, biopharmaceutical, nutraceutical, nutrition, consumer, and medical devices and disposables. The Company's product portfolio in the pharmaceutical range includes therapeutic areas, such as cardiovascular, respiratory care, gastroenterology, pain management, central nervous system (CNS), ortho care, neuropsychiatry, probiotics, antibiotics, and nutritional care. Its pharmaceutical products include Analgesic & Muscle-Relaxant, Anti-Allergy & Anti-Tussive, Anti-Anemic, Anti-Chelating, Anti-infective, Anti-Neoplastic, Anti-Thrombotic, Cardiovascular, Endocrinology & Metabolism. It also focuses on specialty generic branded portfolios and targeting differentiated products. Its subsidiaries include IBL HealthCare Limited, Searle Pharmaceuticals (Private) Limited, and others.
Sector
Pharmaceuticals
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
60.4
PKR
Average target price
65
PKR
Spread / Average Target
+7.62%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +17.33% | 84.71M | |
| +32.36% | 695B | |
| +26.51% | 568B | |
| -4.40% | 361B | |
| +19.46% | 330B | |
| +3.50% | 283B | |
| +17.08% | 239B | |
| +8.08% | 204B | |
| -7.81% | 198B | |
| +8.62% | 168B |
- Stock Market
- Equities
- SEARL Stock
